Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Verizon Communications Inc (VZ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Verizon Communications Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.77 (market cap $4.49B), while Verizon Communications Inc trades at $42.9 (market cap $177.84B). The key difference: Verizon Communications Inc is far larger — about 39.6× ACADIA Pharmaceuticals Inc.'s market cap, and Verizon Communications Inc pays a 6.64% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | VZ | |
|---|---|---|
Market Cap | $4.49B | $177.84B |
Sector | Health | Media |
52-Week High | $28.06 | $51.38 |
52-Week Low | $20.06 | $38.40 |
Enterprise Value | $3.69B | $365.34B |
Volume | — | 22,584,735 |
Dividend Yield | — | 6.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Verizon (VZ) trades at $42.59, up 0.07% on the day, with a bearish technical signal but attractive valuation metrics including a P/E of 10.26 and dividend yield near 6.7%. Recent quarters show consistent earnings beats, with Q1 2026 EPS of $1.28 exceeding expectations. The company maintains strong cash flow from operations at $37.14 billion in 2025, supporting its dividend payments. However, the stock has underperformed the wireless industry over the past year, declining 0.4% versus sector growth of 102.8% (Zacks Investment Research, 2026-07-07).
Outlook: Verizon offers value and income appeal with a low P/E and high dividend, but faces competitive pressures from SpaceX's Starlink and technical bearishness. Risks include high debt levels and industry disruption. Analyst consensus price target is $50.25, suggesting 18% upside potential, with 37% buy ratings indicating cautious optimism amid challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Verizon Communications Inc
Verizon Communications Inc. is an integrated telecommunications company that provides wire line voice and data services, wireless services, Internet services, and published directory information. The Company also provides network services for the federal government including business phone lines, data services, telecommunications equipment, and payphones.
Read more on VZ →
